Synergistic effects of combined administration of mirtazapine and a stimulant compound

Details for Australian Patent Application No. 2005304751 (hide)

Owner New River Pharmaceuticals Inc.

Inventors Kirk, Randal J.

Agent Davies Collison Cave

Pub. Number AU-A-2005304751

PCT Pub. Number WO2006/052880

Priority 60/625,582 08.11.04 US; 60/625,946 09.11.04 US

Filing date 7 November 2005

Wipo publication date 18 May 2006

International Classifications

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Event Publications

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/052880 Priority application(s): WO2006/052880

20 December 2007 Assignment before Grant

  New River Pharmaceuticals Inc. The application has been assigned to Shire LLC

5 November 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005304757-Metabolites of certain [1,4]diazepino[6,7,1-iJ]quinoline derivatives and methods of preparation and use thereof

2005304745-Metatarsal implant